Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 14 of 14 entries
Sorted by: Best Match Show Resources per page
Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect".

The journal of prevention of Alzheimer's disease

Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M.
PMID: 29199323
J Prev Alzheimers Dis. 2016;3(4):219-228. doi: 10.14283/jpad.2016.115.

BACKGROUND: Tramiprosate is an oral amyloid anti-aggregation agent that reduces amyloid oligomer toxicity in preclinical studies and was evaluated in two 78-week trials in North America and Western Europe that enrolled 2,025 patients with Mild to Moderate Alzheimer's Disease....

Cite
Abushakra S, Porsteinsson A, Vellas B, et al. Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect". J Prev Alzheimers Dis. 2016;3(4):219-228doi: 10.14283/jpad.2016.115.
Abushakra, S., Porsteinsson, A., Vellas, B., Cummings, J., Gauthier, S., Hey, J. A., Power, A., Hendrix, S., Wang, P., Shen, L., Sampalis, J., & Tolar, M. (2016). Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect". The journal of prevention of Alzheimer's disease, 3(4), 219-228. https://doi.org/10.14283/jpad.2016.115
Abushakra, S, et al. "Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect"." The journal of prevention of Alzheimer's disease vol. 3,4 (2016): 219-228. doi: https://doi.org/10.14283/jpad.2016.115
Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, Power A, Hendrix S, Wang P, Shen L, Sampalis J, Tolar M. Clinical Benefits of Tramiprosate in Alzheimer's Disease Are Associated with Higher Number of APOE4 Alleles: The "APOE4 Gene-Dose Effect". J Prev Alzheimers Dis. 2016;3(4):219-228. doi: 10.14283/jpad.2016.115. PMID: 29199323.
Copy Download .nbib Format: NLM
Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects.

Clinical pharmacology in drug development

Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S.
PMID: 27121673
Clin Pharmacol Drug Dev. 2013 Apr;2(2):186-94. doi: 10.1002/cpdd.14. Epub 2013 Mar 16.

ELND005 (scyllo-inositol), an endogenous inositol stereoisomer, is being investigated as an oral treatment for Alzheimer's disease (AD). Pharmacokinetics of ELND005 in plasma, cerebrospinal fluid (CSF), and brain was characterized in healthy young subjects. Eight men received 2000 mg ELND005...

Cite
Liang E, Garzone P, Cedarbaum JM, et al. Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. Clin Pharmacol Drug Dev. 2013;2(2):186-94doi: 10.1002/cpdd.14.
Liang, E., Garzone, P., Cedarbaum, J. M., Koller, M., Tran, T., Xu, V., Ross, B., Jhee, S. S., Ereshefsky, L., Pastrak, A., & Abushakra, S. (2013). Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. Clinical pharmacology in drug development, 2(2), 186-94. https://doi.org/10.1002/cpdd.14
Liang, Earvin, et al. "Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects." Clinical pharmacology in drug development vol. 2,2 (2013): 186-94. doi: https://doi.org/10.1002/cpdd.14
Liang E, Garzone P, Cedarbaum JM, Koller M, Tran T, Xu V, Ross B, Jhee SS, Ereshefsky L, Pastrak A, Abushakra S. Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. Clin Pharmacol Drug Dev. 2013 Apr;2(2):186-94. doi: 10.1002/cpdd.14. Epub 2013 Mar 16. PMID: 27121673.
Copy Download .nbib Format: NLM
Showing 13 to 14 of 14 entries